BibTex format
@article{Andreas:2016:10.1038/cti.2016.43,
author = {Andreas, NJ and Al-Khalidi, A and Jaiteh, M and Clarke, E and Hyde, MJ and Modi, N and Holmes, E and Kampmann, B and Mehring-Le, Doare KEK},
doi = {10.1038/cti.2016.43},
journal = {Clinical and Translational Immunology},
title = {Role of human milk oligosaccharides in Group B Streptococcus colonisation},
url = {http://dx.doi.org/10.1038/cti.2016.43},
volume = {5},
year = {2016}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - Group B Streptococcus (GBS) infection is a major cause of morbidity and mortality in infants. The major risk factor for GBSdisease is maternal and subsequent infant colonisation. It is unknown whether human milk oligosaccharides (HMOs) protectagainst GBS colonisation. HMO production is genetically determined and linked to the Lewis antigen system. We aimed toinvestigate the association between HMOs and infant GBS colonisation between birth and postnatal day 90. Rectovaginal swabswere collected at delivery, as well as colostrum/breast milk, infant nasopharyngeal and rectal swabs at birth, 6 days and days60–89 postpartum from 183 Gambian mother/infant pairs. GBS colonisation and serotypes were determined using culture andPCR. 1H nuclear magnetic resonance spectroscopy was used to characterise the mother’s Lewis status and HMO profile in breastmilk. Mothers who were Lewis-positive were significantly less likely to be colonised by GBS (X2 = 12.50, Po0.001). Infants ofLewis-positive mothers were less likely GBS colonised at birth (X2 = 4.88 P = 0.03) and more likely to clear colonisation betweenbirth and days 60–89 than infants born to Lewis-negative women (P = 0.05). There was no association between Secretor statusand GBS colonisation. In vitro work revealed that lacto-N-difucohexaose I (LNDFHI) correlated with a reduction in the growth ofGBS. Our results suggest that HMO such as LNDFHI may be a useful adjunct in reducing maternal and infant colonisation andhence invasive GBS disease. Secretor status offers utility as a stratification variable in GBS clinical trials.
AU - Andreas,NJ
AU - Al-Khalidi,A
AU - Jaiteh,M
AU - Clarke,E
AU - Hyde,MJ
AU - Modi,N
AU - Holmes,E
AU - Kampmann,B
AU - Mehring-Le,Doare KEK
DO - 10.1038/cti.2016.43
PY - 2016///
SN - 2050-0068
TI - Role of human milk oligosaccharides in Group B Streptococcus colonisation
T2 - Clinical and Translational Immunology
UR - http://dx.doi.org/10.1038/cti.2016.43
UR - http://hdl.handle.net/10044/1/34648
VL - 5
ER -